FDA clears Bioventus’ neXus BoneScalpel Access system

Bioventus (NSDQ:BVS) announced today that it received FDA 510(k) clearance for its neXus BoneScalpel Access handpiece.

Durham, North Carolina-based Bioventus said in a news release that the neXus ultrasonic surgical aspirator system — a next-generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm — powers the BoneScalpel Access device.

The neXus system combines all features of soft and hard tissue removal in a single, fully integrated offering, Bioventus said. Its indications under FDA 510(k) clearance include use in the fragmentation and aspiration of soft and hard tissue in neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, plastic and reconstructive surgery, general surgery, orthopedic surgery, gynecology and more.

Bioventus plans to launch BoneScalpel Access — a product the company picked up through its recent acquisition of Misonix — in 2022. The neXus ultrasonic surgical aspirator s…

Read more
  • 0

Bioventus closes acquisition of Misonix

Bioventus (NSDQ:BVS) announced today that it completed its previously announced acquisition of Misonix for an undisclosed amount.

Durham, N.C.-based Bioventus said in a news release that Misonix, a developer of minimally invasive therapeutic ultrasonic technologies and regenerative medicine, has become a wholly-owned subsidiary following the acquisition for cash and common stock.

Misonix’s offerings will add to Bioventus’ pain treatment, restorative therapies and bone graft substitutes product portfolio, the company said. There will be a significant sales force employed to focus on surgical applications in spinal fusion, neurosurgery and wound treatments.

As of the effective time of the transaction, Misonix stockholders hold the right to receive either 1.6839 shares of Bioventus Class A common stock or $28 in cash, without interest, for each share of Misonix common stock they hold, subject to proration based on an aggregate maximum cash amount paya…

Read more
  • 0

Bioventus cleared to acquire Misonix

Bioventus (NSDQ:BVS) this week announced that its stockholders approved the merger and acquisition of Misonix for an undisclosed amount.

The Durham, N.C.-based company’s stockholders approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix for the previously announced merger of the two companies. Through the deal, Misonix will become a wholly-owned subsidiary of Bioventus.

“We are pleased by the outcome of today’s vote and thank our stockholders for supporting the acquisition,” Bioventus CEO Ken Reali said in a news release. “The combination with Misonix creates significant value and provides a deeper global portfolio of pain treatments, restorative therapies and surgical solutions for patients. We are excited to welcome the Misonix team to Bioventus.”

“We are excited about our progress in completing the transaction that will drive long-term value for Misonix shareholders and look forward to closing,” Misonix…

Read more
  • 0